A Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM-3379

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
Mirum Pharmaceuticals, Inc.
Study ID
NCT07712718
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteers

Eligibility Criteria

Sex
MALE
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • [14C]-MRM-3379 — DRUG
    Oral capsule administered on Day 1 only.

Study Details

This is a Phase 1, open label study in healthy male participants to study the Absorption, Distribution, Metabolism, and Excretion of \[14C\]-MRM-3379 drug following a single oral dose.

Key Dates

First listed
Jul 17, 2026
Start date
May 29, 2026
Status verified
Jul 2026
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
8 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Healthy Male Volunteers
    Participants in this arm will receive a single dose of 5 mg \[14C\]-MRM-3379.

Primary Outcome Measure

Total radioactivity recovery of MRM-3379 in urine and feces [ Time Frame: Up to 11 days post dose ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research Unit IncMadisonWisconsin53704
Hunter Walton
[email protected]
608-210-5454

Find similar trials in Madison, WI

By research site
Fortrea Clinical Research Unit Inc· Madison, WI

Related Studies